Limfoma klinikiniai tyrimai Koloradas
16 tyrimai dėl Limfoma ieško dalyvių vietose Koloradas.
Miestai Koloradas
Oficialus tyrimo tekstas (anglų kalba)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 0 iki 38 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06131801A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- University Of Colorado, Aurora
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07015242A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital Colorado - Anschutz Medical Campus, Aurora
Renkami dalyviai1/2 fazė
Iki 25 metų · Visoms lytims · Atnaujinta 2026-09-25 · NCT04094610A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Colorado Blood Institute, Denver
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT07221500Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- University of Colorado, Aurora
- Colorado Blood Cancer Institute (Sarah Cannon), Denver
Renkami dalyviai1 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-09-15 · NCT05798897CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Children's Hospital Colorado, Aurora
Renkami dalyviai1/2 fazė
12 Months – 21 Years · Visoms lytims · Atnaujinta 2026-09-11 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Denver
Renkami dalyviai3 fazė
Amžius nuo 18 iki 18 · Visoms lytims · Atnaujinta 2026-09-08 · NCT07509151Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai1/2 fazė
Amžius nuo 13 iki 90 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-04 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-13 · NCT04792489A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0019), Aurora
Renkami dalyviai1/2 fazė
6 Months – 17 Years · Visoms lytims · Atnaujinta 2026-07-06 · NCT02332668A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-02 · NCT05131022Survivors Uniting for Remote Guided Exercise
- Human Performance Clinical Research Lab, Fort Collins
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-31 · NCT07290309A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-20 · NCT04830137Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- University of Colorado Anschutz Medical Campus, Aurora
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-22 · NCT04234048Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.